<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biocardia Inc — News on 6ix</title>
<link>https://6ix.com/company/biocardia-inc</link>
<description>Latest news and press releases for Biocardia Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biocardia-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354b7778dffbe2df0e51b4.webp</url>
<title>Biocardia Inc</title>
<link>https://6ix.com/company/biocardia-inc</link>
</image>
<item>
<title>BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-allowance-of-japanese-patent-on-proprietary-heart3dtm-fusion-imaging-software-for-procedure-planning-and-realtime-navigation-during-cardiamp-cell-therapy-procedures</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-allowance-of-japanese-patent-on-proprietary-heart3dtm-fusion-imaging-software-for-procedure-planning-and-realtime-navigation-during-cardiamp-cell-therapy-procedures</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the allowance of Japanese Patent, “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.” This patent adds further protection to BioCardia’s proprietary Heart3D™ Fusion Imaging (Heart3D) software intended for treatment planning and real-time navigation</description>
</item>
<item>
<title>BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-and-japan-pmda-align-on-acceptability-of-cardiamp-clinical-data-to-support-regulatory-approval-in-ischemic-heart-failure</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-and-japan-pmda-align-on-acceptability-of-cardiamp-clinical-data-to-support-regulatory-approval-in-ischemic-heart-failure</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported a positive outcome in its formal clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA). PMDA has determined that the clinical safety and efficacy evidence for the CardiAMP® Cell Therapy in ischemic heart failure is likely sufficient to support market</description>
</item>
<item>
<title>BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-files-request-for-meeting-with-fda-to-discuss-accelerated-approval-pathway-for-cardiampr-system-in-ischemic-heart-failure</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-files-request-for-meeting-with-fda-to-discuss-accelerated-approval-pathway-for-cardiampr-system-in-ischemic-heart-failure</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the</description>
</item>
<item>
<title>BioCardia Reports 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-reports-2025-business-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-reports-2025-business-highlights-and-financial-results</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the</description>
</item>
<item>
<title>BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-to-host-2025-financial-results-and-corporate-update-conference-call-on-march-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-to-host-2025-financial-results-and-corporate-update-conference-call-on-march-24-2026</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment</description>
</item>
<item>
<title>BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-pre-submission-approval-package-for-helix-transendocardial-delivery-catheter-accepted-by-fda</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-pre-submission-approval-package-for-helix-transendocardial-delivery-catheter-accepted-by-fda</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>FDA Substantive Review and Meeting Scheduled for Early Q2 SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer</description>
</item>
<item>
<title>BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-late-breaking-echocardiography-clinical-results-from-cardiamp-hf-trial-presented-at-technology-and-heart-failure-therapeutics-tht</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-late-breaking-echocardiography-clinical-results-from-cardiamp-hf-trial-presented-at-technology-and-heart-failure-therapeutics-tht</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-files-pre-submission-fda-141500081</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-files-pre-submission-fda-141500081</guid>
<pubDate>Tue, 10 Feb 2026 14:15:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to FDA under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter (“Helix”) for intramyocardial therapeutic and diagnostic agent delivery. The data supporting safety and effectiveness for the Helix Pre-Submission</description>
</item>
<item>
<title>BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-breaking-echocardiography-results-130000853</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-breaking-echocardiography-results-130000853</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf</description>
</item>
<item>
<title>BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-cell-therapy-ischemic-heart-130000258</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-cell-therapy-ischemic-heart-130000258</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on our CardiAMP Cell Therapy intended for treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). The meeting was held in further preparation for formal clinic</description>
</item>
<item>
<title>BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-election-board-director-130000519</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-election-board-director-130000519</guid>
<pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025. “We are very pleased to welcome Mr. Slosman to our Board,</description>
</item>
<item>
<title>BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-present-december-2025-csi-133000830</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-present-december-2025-csi-133000830</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participate at the CSI Focus Devices in Heart Failure this week in Frankfurt, Germany. BioCardia’s President and Chief Executive Officer, Peter Altman, PhD, will make an invited presentation entitled, “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejec</description>
</item>
<item>
<title>BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-strengthens-leadership-team-addition-131500860</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-strengthens-leadership-team-addition-131500860</guid>
<pubDate>Mon, 24 Nov 2025 13:15:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice P</description>
</item>
<item>
<title>BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-reports-third-quarter-2025-214000688</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-reports-third-quarter-2025-214000688</guid>
<pubDate>Wed, 12 Nov 2025 21:40:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2025 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss busi</description>
</item>
<item>
<title>BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-henry-ford-health-133000254</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-henry-ford-health-133000254</guid>
<pubDate>Mon, 10 Nov 2025 13:30:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled at Henry Ford Health in its ongoing Phase 3 CardiAMP® HF II clinical trial for patients with ischemic heart failure of reduced ejection fraction (“HFrEF”). “The CardiAMP-HF trial, in which Henry Ford Health participated, was groundbreaking for the field</description>
</item>
<item>
<title>BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-host-q3-2025-corporate-002900049</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-host-q3-2025-corporate-002900049</guid>
<pubDate>Thu, 06 Nov 2025 00:29:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participant</description>
</item>
<item>
<title>BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-university-wisconsin-enrolls-120000259</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-university-wisconsin-enrolls-120000259</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial. “CardiAMP cell therapy has shown evidence of benefit for ischemic heart failure patients with elevated markers of heart stress, despite</description>
</item>
<item>
<title>BioCardia Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-regains-compliance-nasdaq-listing-120000798</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-regains-compliance-nasdaq-listing-120000798</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market’s Listing Requirements (the “Listing Requirements”). This confirmation follows the Company’s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and adv</description>
</item>
<item>
<title>BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-positive-preliminary-clinical-120000351</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-positive-preliminary-clinical-120000351</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has had a positive preliminary clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on the CardiAMP Heart Failure Trial results previously provided to the agency. The meeting was held in preparation for the formal clinical consultation on acceptability of t</description>
</item>
<item>
<title>BioCardia Announces Pricing of Up To $12 Million Public Offering</title>
<link>https://6ix.com/company/biocardia-inc/news/biocardia-announces-pricing-12-million-131500048</link>
<guid isPermaLink="true">https://6ix.com/company/biocardia-inc/news/biocardia-announces-pricing-12-million-131500048</guid>
<pubDate>Thu, 18 Sep 2025 13:15:00 GMT</pubDate>
<description>$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock and short-term warrants</description>
</item>
</channel>
</rss>